Genentech Defends Lucentis Pricing

The CEO of US-based biotech major Genentech has defended his firm's pricing policies in a recent interview with the Wall Street Journal. Pointing out that the company invested US$1.8bn in R&D in 2006, Dr Levinson claims that premium pricing is an unfortunate but necessary part of the business model. BMI tends to agree, as the high price of clinical trials is pressurising drugmakers, while the majority of biotech companies in the US consistently lose money.

To read the full article, please choose one of the following options: